Ultrasound Guided Continuous Quadratus Lumborum Block Versus Continuous Paravertebral Block In Radical Cystectomy
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03547011 |
|
Recruitment Status :
Completed
First Posted : June 6, 2018
Last Update Posted : January 15, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Pain, Postoperative | Procedure: US guided Quadratus Lumborum block Procedure: US guided Paravertebral block. | Not Applicable |
Show detailed description
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 60 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | Double blinded randomized study. |
| Masking: | Triple (Participant, Care Provider, Outcomes Assessor) |
| Masking Description: | The patients, outcome assessors and care providers are not informed with the block type done. |
| Primary Purpose: | Treatment |
| Official Title: | The Efficacy of Ultrasound Guided Continuous Quadratus Lumborum Block Versus Continuous Paravertebral Block In Radical Cystectomy |
| Actual Study Start Date : | September 16, 2017 |
| Actual Primary Completion Date : | June 30, 2018 |
| Actual Study Completion Date : | July 3, 2018 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: US guided Quadratus Lumborum block
Patients will receive ultrasound guided quadratus lumborum block with 0.3 ml /kg bupivacaine 0.25% on each side with catheter insertion for maintenance doses 0.1ml/kg/hr on each side.
|
Procedure: US guided Quadratus Lumborum block
Patients will receive ultrasound guided quadratus lumborum block with 0.3 ml /kg bupivacaine 0.25% on each side with catheter insertion for maintenance doses 0.1ml/kg/hr on each side. |
|
Active Comparator: US guided Paravertebral block.
Patients will receive ultrasound guided thoracic paravertebral block with 0.3 ml/kg bupivacaine 0.25 % on each side with catheter insertion for maintenance doses 0.1 ml/kg/hr on each side.
|
Procedure: US guided Paravertebral block.
Patients will receive ultrasound guided thoracic paravertebral block with 0.3 ml/kg bupivacaine 0.25 % on each side with catheter insertion for maintenance doses 0.1 ml/kg/hr on each side. |
- analgesic effect [ Time Frame: 72 hours ]Visual Analogue Scale measure and needed postoperative analgesics.0 to 10, as 0 no pain 10 the worst pain.
- Side effects [ Time Frame: 30 days ]numbers of side effects
- length of hospital stay [ Time Frame: 30 days ]Number of days in hospitals
- Patient satisfaction. [ Time Frame: 30 days ]Numbers from 0-10
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 99 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
• After written informed consent from each patient or oral consent if illiteracy prevent a written consent, The present study will be carried out in the Urosurgery department at Alexandria Main University hospital on 60 adult patients scheduled for radical cystectomy, males and females.
-
Patients will be randomly assigned into two equal groups (30 patients each) according to type of the block:
-
Group I:
Patients will receive ultrasound guided quadratus lumborum block with 0.3 ml /kg bupivacaine 0.25% on each side with catheter insertion for maintenance doses 0.1ml/kg/hr on each side.
-
Group II:
Patients will receive ultrasound guided thoracic paravertebral block with 0.3 ml/kg bupivacaine 0.25 % on each side with catheter insertion for maintenance doses 0.1 ml/kg/hr on each side.
Exclusion Criteria:
-
- Patient refusal.
- Coagulopathy/ thrombocytopenia.
- Localized infection at the proposed site of injection.
- Inability to comprehend the scoring systems to be employed due to mental problems.
- known allergy to the drugs to be used (local anesthetics, opioids)
- Opioid tolerance/ dependence
- Back abnormalities.
- Neurological deficits.
-
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03547011
| Egypt | |
| Alexandria Faculty of Medicine | |
| Alexandria, Egypt, 21111 | |
| Principal Investigator: | Mohammad Hazem I Ahmad Sabry, MB,ChB MD | Alexandria Univeristy |
| Responsible Party: | Mohammad Hazem I. Ahmad Sabry, Lecturer of Anesthesia, University of Alexandria |
| ClinicalTrials.gov Identifier: | NCT03547011 |
| Other Study ID Numbers: |
050108380 (13/6/2017) |
| First Posted: | June 6, 2018 Key Record Dates |
| Last Update Posted: | January 15, 2019 |
| Last Verified: | January 2019 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | Data results and statistical analysis. |
| Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Informed Consent Form (ICF) Clinical Study Report (CSR) |
| Time Frame: | Before the start till publishing the study. |
| Access Criteria: | not public only the researchers who can access the study information. |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Pain, Postoperative Postoperative Complications Pathologic Processes Pain Neurologic Manifestations |

